Actively Recruiting
Cognitive Screening in Lung Cancer Patients
Led by European Institute of Oncology · Updated on 2024-12-10
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how lung cancer and its treatments may affect thinking and memory in patients with both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). This observational study aims to understand the occurrence of cognitive impairment during the first year after patients join the study. The European Institute of Oncology is leading this research to better understand cognitive changes in lung cancer patients. The study includes patients diagnosed with lung cancer across all stages (I to IV). There are no drug treatments or interventions involved since this is an observational study, meaning researchers will monitor and assess participants without giving any new treatments. Participants will be observed and evaluated during the first year after enrollment to track cognitive changes. Participants will undergo comprehensive neuropsychological assessments to measure thinking and memory abilities at different times over one year. Researchers will also look for risk factors that might affect cognitive function in lung cancer patients. The study excludes patients with brain metastases, brain radiotherapy, or other neurological or psychiatric disorders. The total time of involvement is up to 12 months, during which participants will complete cognitive tests and other assessments.
CONDITIONS
Brief Title
Cognitive Screening in Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of small-cell or non-small-cell lung cancer (stage I, II, III, or IV)
- Age 18 years or older
- Ability to speak and read the local language fluently
- Willingness to provide signed informed consent
You will not qualify if you...
- Age 70 years or older
- Presence of brain metastases
- Having neurological or psychiatric disorders
- Receiving brain radiotherapy
- Previous diagnosis of lung cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants are observed to assess cognitive impairment and risk factors over time.
Visits occur at baseline and periodically up to 12 months
Trial Site Locations
Total: 1 location
1
Istituto Europeo di Oncologia
Milan, Italy, 20141
Actively Recruiting
Research Team
G
Gabriella Pravettoni
L
Lorenzo Conti
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here